CPT PLA Code for the IMMray™ PanCan-d Test Approved
Immunovia AB (NASDAQ Stockholm: IMMNOV) announced that its American subsidiary, Immunovia, Inc., has recently received approval from the American Medical Association (AMA) for a Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the IMMrayTMPanCan-d test. The code will go into effect on October 1, 2022.
Immunovia is currently in process with the Centers of Medicare & Medicaid Services (CMS) to establish payment for IMMray™ PanCan-d with this PLA code which will be included in the 2023 CMS Clinical Lab Fee Schedule.
"We are very pleased that the AMA has approved a unique CPT PLA code for our IMMray™ PanCan-d test. This is an important step in our ongoing efforts to secure reimbursement for our test," says Philipp Mathieu, CEO and President of Immunovia AB.
CPT codes provide doctors and other health care professionals with a standard language for coding medical services and procedures. It is the most commonly used medical nomenclature in the United States for reporting physician and healthcare professional services, including laboratory tests, under public and private health insurance programs.
PLA Codes supplement the CPT code set approved by the AMA CPT Editorial Panel. They are alpha-numeric CPT codes with a corresponding descriptor for laboratories or manufacturers who want to more precisely identify their test.
Note: Content may be edited for style and length.
Source
